Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 29 peer-reviewed journal articles Updated
Neurology

How Long Does It Take to Recover from CIDP Treatment?

At a Glance

Recovery from CIDP varies: some people improve within weeks, while healing from damage to the nerve fibers can take months or years. Treatment may first stop worsening, and neurologists track progress with strength, walking, and daily-function measures.

Recovering from Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is highly individualized. Because CIDP is a complex disease, there is no single recovery timeline. For many patients, the initial goal of treatment is stabilization—stopping the immune system’s attack on the nerves and preventing further decline—rather than immediate improvement [1].

While some people notice early signs of improvement within a few weeks of starting treatment, maximum functional recovery, especially for sensory issues and fine motor skills, can take months or even years [2].

SAFETY WARNING: General recovery timelines are only estimates. Do not wait if you experience rapidly worsening weakness, repeated falls, an inability to stand, or sudden trouble breathing or swallowing—seek urgent medical attention. Furthermore, never stop or alter your medications (especially corticosteroids, which require careful tapering) without consulting your prescribing clinician, even if you feel the treatment is acting slowly [3].

The Overlapping Phases of Nerve Healing

Nerve healing in CIDP is a complex process. To understand your recovery, it helps to look at a simplified model of the two main types of nerve injury, which often overlap:

  • Repairing Demyelination: CIDP primarily involves inflammation and damage to the myelin sheath (the protective fatty coating around your nerves). Certain treatments can quickly reduce this inflammation and clear circulating factors that block nerve signaling (saltatory conduction) [4]. This can lead to relatively rapid clinical improvements even before the body has fully rebuilt new myelin [5].
  • Recovering from Axonal Loss: In many cases, the inner wire of the nerve (the axon) also becomes damaged. This secondary injury is known as axonal loss [6]. While myelin can be repaired efficiently, axons grow back very slowly. Patients with significant axonal damage face a longer recovery timeline, and some residual weakness or sensory loss may be permanent [7][8].

Specialists use electrodiagnostic testing—specifically nerve conduction studies and electromyography (EMG)—to evaluate the extent of demyelination and axonal loss [9].

(Note: Diagnostic delays are common in rare diseases like CIDP and are not the patient’s fault. While starting immunotherapy earlier helps limit axonal damage, functional gains are still possible later in the disease course [9].)

Expected Response Windows by Treatment

Different treatments have different roles (e.g., initial therapy vs. maintenance) and act at different speeds. The following are approximate windows observed in clinical studies; your personal response may be earlier, later, or present as disease stabilization rather than regained strength.

Treatment Role in CIDP Expected Assessment Window What to Know
Intravenous Immunoglobulin (IVIg) Initial or maintenance Initial response often assessed within a few weeks to months. May stop decline or improve strength relatively quickly in responders, but frequently requires ongoing maintenance cycles [1][10].
Corticosteroids (e.g., prednisone, dexamethasone) Initial or maintenance Often evaluated over several months (e.g., 2 to 6 months). Generally slower to show initial benefit than IVIg [11]. Often produces gradual improvement or stabilization [12]. Must be carefully tapered.
Plasma Exchange (PLEX) Often a rescue or “bridge” therapy Assessed during or shortly after the exchange course (often 3 to 4 weeks). PLEX removes plasma and many circulating proteins, not just antibodies. It can provide rapid improvement, but benefits often wane quickly without long-term maintenance therapy [13][14].
Subcutaneous Immunoglobulin (SCIg) Primarily maintenance Response depends heavily on prior therapy. Mostly used to maintain disease stability after a patient has successfully responded to IVIg [15]. Its onset speed in untreated patients is less predictable [16]. Can cause local injection-site reactions.

Targeted Therapies and Rare Antibodies
For patients who do not respond to standard treatments, specialists may consider other options:

  • Efgartigimod (Vyvgart Hytrulo) is an immune-targeted therapy approved in some regions for CIDP. Clinical trials primarily demonstrated its ability to maintain disease control and delay clinical deterioration in previously treated patients, with some patients showing confirmed clinical improvement over 12 weeks [17].
  • Rituximab is an off-label option with mixed evidence [18]. It is typically reserved for refractory cases or specific, rare CIDP variants (such as anti-NF155 IgG4 antibody-associated disease, which requires specialized blood testing). Responses can be highly variable, sometimes taking weeks to many months to become apparent [19][20].

Tracking Progress: How Will We Know I Am Improving?

Because subjective feelings fluctuate, neurologists rely on objective clinical measurements to guide treatment decisions. Your doctor may track:

  • Grip strength using a dynamometer [21].
  • Walking speed and distance [22].
  • Disability scales (like INCAT or I-RODS), which measure your ability to perform daily tasks like using stairs, dressing, or washing [23].

Age and overlapping conditions also play a role. For example, patients with diabetes may have additional nerve stress (diabetic neuropathy) that can slow recovery or complicate response assessment, emphasizing the need for comprehensive medical care [24][25].

Why Slow Progress Doesn’t Always Mean Treatment Failure

It is incredibly frustrating to wait for nerves to heal, but a lack of rapid improvement does not automatically mean your therapy is failing.

1. Clinical vs. Electrical Improvement
Your physical function often improves before your electrical nerve tests do. Studies following patients for up to 2 years show that walking, hand function, and sensory symptoms can steadily improve even when nerve conduction tests show stable, lingering abnormalities [26][2]. Do not be discouraged if your repeat electrical tests have not normalized.

2. Persistent Symptoms and Residual Damage
Symptoms like fatigue and neuropathic pain can persist for years [27]. These symptoms do not necessarily mean the CIDP inflammation is still active; they can result from residual nerve injury, deconditioning, or medication side effects. These symptoms require specific, separate management, such as neuropathic pain medications or sleep evaluations [28].

3. The Role of Rehabilitation
Medication alone only controls the immune attack; it does not replace the need for physical conditioning. Physical and occupational rehabilitation are critical for maximizing your function [29]. Rather than “pushing through” weakness, rehabilitation in CIDP focuses on:

  • Pacing and energy conservation to avoid overwork weakness.
  • Fall prevention and balance training.
  • The use of assistive devices (like ankle-foot orthotics or canes) to keep you safe while your nerves heal.

If objective measurements show no stabilization or improvement after an appropriate trial period, your neurologist will evaluate whether the dose needs adjusting, if a switch to a different therapy is required, or if the diagnosis needs to be reconsidered [3]. However, slow, steady progress—or simply stopping further decline—is a standard part of living with and recovering from CIDP.

Common questions in this guide

How soon might I notice improvement after IVIg for CIDP?
Some people with CIDP notice early improvement within a few weeks after IVIg, but doctors may assess the response over weeks to months. The first sign may be stabilization or less decline rather than a dramatic return of strength, and ongoing maintenance cycles are often needed.
How long can steroids take to help CIDP?
Corticosteroids often take longer than IVIg, and the response is commonly evaluated over roughly two to six months. Improvement may be gradual or may appear as stabilization, and steroids must be tapered under the prescribing clinician’s supervision.
Can plasma exchange improve CIDP quickly?
Plasma exchange can produce improvement during or shortly after a treatment course, so it may be used as rescue or bridge therapy. Its benefits may fade quickly without a longer-term treatment plan.
Does axonal damage make CIDP recovery take longer?
Yes. Repair of the nerve’s protective covering can allow relatively quick improvement, while recovery from damage to the nerve fiber itself is much slower. Significant axonal loss may lead to recovery over months or years and can leave some weakness or sensory loss.
Does slow progress mean my CIDP treatment is not working?
Not necessarily. Treatment may first stop further decline, and physical function can continue improving even when nerve tests still show abnormalities. Neurologists use measures such as grip strength, walking ability, and daily activities to judge progress.
How can rehabilitation support recovery from CIDP?
Physical and occupational therapy can help with safe strengthening, balance, fall prevention, pacing, energy conservation, and assistive devices. Rehabilitation should be tailored to your weakness and fatigue rather than pushing through symptoms.

Related questions

How Common Is CIDP, and Who Is Most Likely to Get It? Is Nerve Damage From CIDP Permanent or Reversible? Can You Eventually Stop CIDP Treatment and Reach Remission? NF155, CNTN1 & CASPR1: What Do They Mean for Treatment? How Does CIDP Differ From Diabetic Neuropathy? Explained
Show more
What Blood Tests Are Recommended for Suspected CIDP? What Is the IVIG Wear-Off Effect in CIDP Treatment? Why Is a Lumbar Puncture Needed to Help Diagnose CIDP? How Is CIDP Different From ALS, CMT, MMN, and POEMS? Can CIDP Cause One-Sided Symptoms? MADSAM Explained What Is the Difference Between Anti-MAG Neuropathy and CIDP? How CIDP Variants Affect Your Treatment and Prognosis What Causes CIDP, and Can Infections or Vaccines Trigger It? What Should You Do If IVIg or Steroids Fail for CIDP? Autoimmune Nodopathies vs CIDP: What Are the Symptoms? Does CIDP Shorten Life Expectancy? Prognosis Explained Why Is Physical Therapy Important for CIDP Recovery? How Does Efgartigimod (Vyvgart) Work for CIDP Treatment? Is CIDP Hereditary or Contagious? Passing It to Children How Is CIDP Diagnosed and How Long Does Diagnosis Take? Can You Have CIDP With a Borderline or Normal Nerve Study? Can MRI or Ultrasound Diagnose CIDP When Tests Are Unclear? How Do Doctors Distinguish Acute-Onset CIDP From GBS? When Should CIDP, Anti-MAG, or Protein Tests Be Done? Do I Need a Nerve Biopsy or Genetic Test for CIDP? Can You Have CIDP Without Muscle Weakness? Explained

Get notified when new evidence is published on Chronic inflammatory demyelinating polyneuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (29)
  1. 1

    Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

    Bus SR, de Haan RJ, Vermeulen M, et al.

    The Cochrane database of systematic reviews 2024; (2()):CD001797 doi:10.1002/14651858.CD001797.pub4.

    PMID: 38353301
  2. 2

    Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment.

    Ellrichmann G, Gold R, Ayzenberg I, et al.

    Therapeutic advances in neurological disorders 2017; (10(2)):91-101 doi:10.1177/1756285616679369.

    PMID: 28382108
  3. 3

    Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy.

    Kaplan A, Brannagan TH

    Muscle & nerve 2017; (55(4)):476-482 doi:10.1002/mus.25271.

    PMID: 27463215
  4. 4

    Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders.

    Stathopoulos P, Alexopoulos H, Dalakas MC

    Nature reviews. Neurology 2015; (11(3)):143-56 doi:10.1038/nrneurol.2014.260.

    PMID: 25623793
  5. 5

    Antibody- and macrophage-mediated segmental demyelination in chronic inflammatory demyelinating polyneuropathy: clinical, electrophysiological, immunological and pathological correlates.

    Vallat JM, Mathis S, Vegezzi E, et al.

    European journal of neurology 2020; (27(4)):692-701 doi:10.1111/ene.14133.

    PMID: 31769579
  6. 6

    Early axonal loss predicts long-term disability in chronic inflammatory demyelinating polyneuropathy.

    Al-Zuhairy A, Jakobsen J, Krarup C

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2021; (132(4)):1000-1007 doi:10.1016/j.clinph.2020.12.017.

    PMID: 33581994
  7. 7

    Axonal loss at time of diagnosis as biomarker for long-term disability in chronic inflammatory demyelinating polyneuropathy.

    Al-Zuhairy A, Jakobsen J, Moldovan M, Krarup C

    Muscle & nerve 2022; (66(6)):715-722 doi:10.1002/mus.27722.

    PMID: 36217677
  8. 8

    Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.

    Alcantara M, Hartung HP, Lawo JP, et al.

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2021; (132(9)):2184-2190 doi:10.1016/j.clinph.2021.05.018.

    PMID: 34293528
  9. 9

    Early therapy initiation is crucial in chronic inflammatory demyelinating polyneuropathy: prospective multimodal data from the German INHIBIT registry.

    Schumacher A, Hieke A, Spenner M, et al.

    Journal of neurology 2025; (272(1)):100 doi:10.1007/s00415-024-12860-w.

    PMID: 39775066
  10. 10

    The Results of ADVANCE-CIDP IVIG Trial: Intravenous Immunoglobulin 10% Therapy With GAMMAGARD LIQUID/Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

    Pasnoor M, Anderson-Smits C, Levine T, et al.

    European journal of neurology 2025; (32(4)):e70110 doi:10.1111/ene.70110.

    PMID: 40247653
  11. 11

    Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).

    Bus SRM, Zambreanu L, Abbas A, et al.

    Trials 2021; (22(1)):155 doi:10.1186/s13063-021-05083-1.

    PMID: 33608058
  12. 12

    [Variables associated with a good response to steroids in chronic inflammatory demyelinating polyradiculoneuropathy].

    Fuentealba S M, Molina D I, Vera-Calzaretta A, et al.

    Revista medica de Chile 2020; (148(5)):594-601 doi:10.4067/S0034-98872020000500594.

    PMID: 33399752
  13. 13

    Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.

    Oaklander AL, Lunn MP, Hughes RA, et al.

    The Cochrane database of systematic reviews 2017; (1()):CD010369 doi:10.1002/14651858.CD010369.pub2.

    PMID: 28084646
  14. 14

    Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

    Mehndiratta MM, Hughes RA, Pritchard J

    The Cochrane database of systematic reviews 2015; CD003906 doi:10.1002/14651858.CD003906.pub4.

    PMID: 26305459
  15. 15

    Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.

    Bril V, Hadden RDM, Brannagan TH, et al.

    Journal of the peripheral nervous system : JPNS 2023; (28(3)):436-449 doi:10.1111/jns.12573.

    PMID: 37314318
  16. 16

    Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.

    Markvardsen LH, Sindrup SH, Christiansen I, et al.

    European journal of neurology 2017; (24(2)):412-418 doi:10.1111/ene.13218.

    PMID: 28000311
  17. 17

    Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.

    Allen JA, Lin J, Basta I, et al.

    The Lancet. Neurology 2024; (23(10)):1013-1024 doi:10.1016/S1474-4422(24)00309-0.

    PMID: 39304241
  18. 18

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Current Therapeutic Approaches and Future Outlooks.

    Rajabally YA

    ImmunoTargets and therapy 2024; (13()):99-110 doi:10.2147/ITT.S388151.

    PMID: 38435981
  19. 19

    Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.

    Querol L, Rojas-García R, Diaz-Manera J, et al.

    Neurology(R) neuroimmunology & neuroinflammation 2015; (2(5)):e149 doi:10.1212/NXI.0000000000000149.

    PMID: 26401517
  20. 20

    Prospective open-label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies.

    Doneddu PE, Cocito D, Fazio R, et al.

    Journal of neurology, neurosurgery, and psychiatry 2024; (95(9)):838-844 doi:10.1136/jnnp-2023-332844.

    PMID: 38729746
  21. 21

    Evaluating Grasp Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Using Dynamometers: A Comprehensive Review.

    Tsoumanis P, Chatzoglou T, Smyris TI, et al.

    Journal of clinical medicine research 2025; (17(3)):136-144 doi:10.14740/jocmr6179.

    PMID: 40115839
  22. 22

    Changes in spatiotemporal gait parameters following intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy.

    Vo ML, Chin RL, Miranda C, Latov N

    Muscle & nerve 2017; (56(4)):732-736 doi:10.1002/mus.25553.

    PMID: 28085193
  23. 23

    Chronic Inflammatory Demyelinating Polyneuropathy and Variants.

    Stino AM, Barohn RJ, Katz JS, Dimachkie MM

    Neurologic clinics 2025; (43(4)):761-780 doi:10.1016/j.ncl.2025.05.015.

    PMID: 41161995
  24. 24

    The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy.

    Hagen KM, Ousman SS

    Journal of neuroinflammation 2021; (18(1)):78 doi:10.1186/s12974-021-02113-2.

    PMID: 33752693
  25. 25

    Efficacy of intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy with or without diabetes: insights from a multicenter prospective comparative study.

    Macwan SP, Mahajan S, Novak P, et al.

    Therapeutic advances in neurological disorders 2025; (18()):17562864251401496 doi:10.1177/17562864251401496.

    PMID: 41446323
  26. 26

    Tacrolimus treatment for relapsing-remitting chronic inflammatory demyelinating polyradiculoneuropathy: Two case reports.

    Zhu WJ, Da YW, Chen H, et al.

    World journal of clinical cases 2022; (10(5)):1709-1715 doi:10.12998/wjcc.v10.i5.1709.

    PMID: 35211613
  27. 27

    Fatigue, Pain, Anxiety and Depression in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

    Merkies IS, Kieseier BC

    European neurology 2016; (75(3-4)):199-206 doi:10.1159/000445347.

    PMID: 27077919
  28. 28

    European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.

    Van den Bergh PYK, van Doorn PA, Hadden RDM, et al.

    European journal of neurology 2021; (28(11)):3556-3583 doi:10.1111/ene.14959.

    PMID: 34327760
  29. 29

    Unconventional treatments for chronic inflammatory demyelinating polyneuropathy.

    Rajabally YA

    Neurodegenerative disease management 2017; (7(5)):331-342 doi:10.2217/nmt-2017-0017.

    PMID: 29043889

This page about CIDP recovery timelines is for informational purposes only and does not constitute medical advice. Consult your neurologist before changing treatment and seek urgent care for rapidly worsening weakness or trouble breathing or swallowing.